Use for the shortest duration required to achieve control of asthma symptoms. Only use long-term in patients whose asthma cannot be adequately controlled on asthma controller medications. Not for relief of acute asthma symptoms. Do not stop treatment abruptly. Consider increasing corticosteroid therapy in case of sudden & progressive deterioration in asthma control. Consider additional corticosteroid therapies & administration of antibiotics if asthma/COPD exacerbation is associated w/ infection. Possible development of pneumonia in patients w/ COPD. Possible systemic effects include Cushing's syndrome, Cushingoid features, adrenal suppression, growth retardation in childn & adolescents, decrease in bone mineral density, cataract, glaucoma & central serous chorioretinopathy. Possibility of impaired adrenal response in emergency & elective situations likely to produce stress. Regularly monitor adrenocortical function in patients transferring from oral steroid therapy to inhaled therapy. Consider very rare reports of increases in blood glucose levels when prescribing to patients w/ history of DM. Immediately discontinue treatment in case of paradoxical bronchospasm. Avoid concomitant use of fluticasone propionate & ritonavir. Caution when co-administered w/ strong CYP3A4 inhibitors (eg, ketoconazole). Caution in patients w/ active or quiescent pulmonary TB; thyrotoxicosis; pre-existing CV disease; predisposition to low levels of serum K. Consider administration during pregnancy & lactation only if expected benefit to mother is greater than any possible risk to foetus/child. No data available for use in childn <4 yr. Regularly monitor height of childn receiving prolonged treatment w/ inhaled corticosteroids.
Accuhaler Contains lactose. Closely monitor patients w/ hepatic disease.
Inhaler Not indicated for initiation of bronchodilator therapy in COPD.
Sign Out
